STOCK TITAN

Cardiff Lexingto Stock Price, News & Analysis

CDIX OTC

Welcome to our dedicated page for Cardiff Lexingto news (Ticker: CDIX), a resource for investors and traders seeking the latest updates and insights on Cardiff Lexingto stock.

Cardiff Lexington Corporation (OTCQB: CDIX) is a healthcare holding company focused on acquiring and building middle-market niche health care clinics in Orthopedics, Spine Care, and Pain Management. This news page aggregates company-issued updates and market-facing announcements that reflect how Cardiff Lexington and its Nova Ortho and Spine subsidiary are progressing operationally, financially, and strategically.

Readers can find earnings releases detailing quarterly and year-to-date financial performance, including revenue trends, gross profit, operating income, net loss, and non-GAAP measures such as adjusted EBITDA. These releases often discuss the impact of one-time non-cash adjustments, changes in interest expense related to the company’s line of credit, and enhancements to internal controls over financial reporting.

The news flow also includes corporate governance and leadership updates, such as the planned retirement of long-serving Chairman Daniel Thompson and the appointment of Chief Executive Officer Alex Cunningham as Chairman of the Board. Cardiff Lexington uses press releases to explain these changes and to describe how its leadership team is shaping strategy and operations.

Investors following CDIX can track capital markets developments through announcements about the company’s uplisting strategy, including the 1-for-3 reverse stock split intended to support Nasdaq Capital Market listing requirements and the filing of a Form S-1 registration statement. Additional releases highlight advisory relationships, such as the engagement of Greentree Financial Group to assist with governance, financial reporting, and public markets compliance.

Operationally, Cardiff Lexington’s news coverage features updates from Nova Ortho and Spine, including expansion into underserved and rural areas of Florida and the performance of procedures at partner hospitals. By reviewing this news feed, investors and observers can monitor Cardiff Lexington’s financial reporting schedule, conference call announcements, and ongoing efforts to grow its orthopedic, spine care, and pain management platform.

Rhea-AI Summary

Cardiff Lexington (OTC Pink:CDIX) has announced the opening of its 12th Nova Ortho and Spine location in Orlando, Florida, set to open on August 5, 2024. This new 1,600 square foot facility marks the company's 11th location in Florida and establishes a presence in the state's fourth-largest city. Nova Ortho and Spine specializes in providing diagnostic and surgical services for traumatic injury victims, with revenue primarily derived from various insurance policies.

CEO Alex Cunningham emphasized that this expansion aligns with the company's growth strategy, enhancing visibility and patient access in larger metropolitan areas. Dr. Kevin Fitzgerald, Managing Director of Nova Ortho and Spine, highlighted the company's strong referral source and high patient satisfaction ratings as key factors in choosing Orlando for their newest location.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Cardiff Lexington (OTC PINK: CDIX) announced the cancellation of its Senior Secured Convertible Promissory Note, 8% Convertible Secured Redeemable Note, and series R preferred stock through an agreement with GHS Investments. In exchange, a new fixed amount settlement promissory note of $535,000 was issued, which bears no interest and requires fixed payments. CEO Alex Cunningham highlighted the elimination of convertible debt as a significant step towards simplifying and strengthening the company's capital structure. The company reported sequential revenue growth, a strong gross margin of 64% in Q1 2024, and a net income of $3 million for the full year 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Cardiff Lexington (OTC Pink: CDIX) announced on June 11, 2024, the appointment of Shannon Vitale as controller and LaTanga Hickman as staff accountant to enhance its financial operations and support anticipated growth. Vitale brings over 15 years of experience in accounting and compliance, previously holding roles at Energy Focus and The NRP Group. Hickman, with over a decade of experience, has worked in various sectors including real estate and healthcare, most recently at Gas Xpress Development. The company aims to strengthen its finance team and drive strategic initiatives with these new additions. The role of chief accounting officer has been eliminated, and Zia Choe has left the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Cardiff Lexington (CDIX) reported a 12% sequential revenue growth in the first quarter of 2024, with a 64% gross profit margin. The operating income decreased due to scaling expenses and stock compensation, but excluding these, it showed a 48% sequential increase. The company is focused on strategic investments to support future growth and aims to uplist to a major U.S. exchange. With improved balance sheet metrics, Cardiff Lexington aims to expand its market presence and drive long-term growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-75.11%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50%
Tags
management
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
100%
Tags
management

FAQ

What is the current stock price of Cardiff Lexingto (CDIX)?

The current stock price of Cardiff Lexingto (CDIX) is $2.417 as of April 1, 2026.

What is the market cap of Cardiff Lexingto (CDIX)?

The market cap of Cardiff Lexingto (CDIX) is approximately 36.6M.